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Abstract
As a result of sub-optimal immunization levels, measles has re-emerged in the EU since 2008 (30 567 cases in 2011), and nearly half of the
cases reported are in France. Our objectives were to assess knowledge, attitudes, beliefs and practices of French general practitioners (GPs)
towards measles and measles–mumps–rubella (MMR) vaccination. In 2012, we surveyed 329 GPs in southeastern France. Forty-five percent
reported that they saw patients with measles in 2011. They considered the risk of complications low among 2–5-year-old children and
young adults without co-morbidity. Twenty percent knew that two MMR doses are 99% effective in preventing measles. Nearly all (95%)
GPs stated that they verified the MMR status for patients <30 years old in 2011 (42% systematically, 37% often, 15% sometimes).
Seventy-nine percent reported proposing MMR vaccination to non-immune relatives in contact with a patient with measles. Participation in
continuing medical education courses and considering measles to be a serious disease were independently associated with such
post-exposure vaccination. GPs considered the following were potential barriers to the second dose of MMR (MMR2): parents/patients’
belief that measles is harmless (80%), parents/patients’ fear of the vaccine’s side effects (50%), difficulty in documenting vaccination (48%)
and lack of reminders for MMR2 (16%). Finally, some GPs also had misconceptions about the severity of measles (13%) and the usefulness of
MMR2 (12%), which also served as barriers. In conclusion, it is essential to raise GPs’ awareness of this disease and fill any gaps in their
knowledge, by providing them with evidence-based information on measles and MMR vaccination.
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Introduction
All countries in the European region of the World Health
Organization have renewed their commitment to eliminate
measles transmission by 2015 [1]. This elimination is a feasible
target but requires vaccination coverage >95% with two doses
of a measles–mumps–rubella vaccine (MMR) [1]. Measles has
re-emerged in the EU recently as the result of sub-optimal
immunization levels that have increased susceptible popula-
tions [1,2]. More than half these cases have been reported in
France: nearly 15 000 cases in 2011, including 714 of severe
measles-related pneumonia, 16 of acute measles encephalitis
and six measles-related deaths, compared with 30 567 cases in
Europe that year [1–3]. Together with France, four countries
—Italy, Romania, Spain and Germany—accounted for >90% of
all measles cases reported in 2011 [1,2]. The measles outbreak
in France began in 2008. The number of reported cases has
decreased sharply since May 2011 [3]. The proportion of cases
 20 years old reached 38% during the first half of 2010 [3,4].
Nonetheless, France has promoted measles vaccination for
years, with national and regional campaigns in place since 1990
[3,4]. A trivalent MMR vaccine has been recommended since
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1983 and available free of charge since 1999 [3,4]. Health
authorities launched a national plan to eliminate measles in
2005 and strengthened it in 2009 [3–5]. The European
Immunization Weeks in 2009, 2010 and 2011 provided an
opportunity to reinforce communication, focusing especially
on vaccination recommendations [4]. A communication
campaign took place in France from September 2011 to
February 2012.
The first dose (MMR1) is currently recommended at the age
of 12 months and the second dose (MMR2) during the second
year of life [3]. Since 1997, a catch-up measles vaccination
programme with two doses has been recommended for
children born in 1992 or later; in 2011, it was extended to
everyone born in or after 1980 [3]. Children <16 years old are
usually vaccinated by general practitioners (GPs) or paediatri-
cians, and adults by GPs (or occupational physicians). Measles
has been a mandatory notifiable disease in France since
mid-2005, and guidelines recommend confirming all clinically
suspected cases by either serology + PCR in saliva samples or
by serology alone in serum samples [3,5]. Physicians are
advised to report all clinically suspected cases to health
authorities immediately; the latter follow up and eventually
classify cases as clinically, laboratory or epidemiologically
confirmed [3,5].
Measles incidence and MMR coverage rates vary regionally
throughout France [3]. The southeastern region is character-
ized by vaccination coverage below the national average: 86%
for MMR1 and 40% for MMR2 in 2003–04 for children aged
15 years, compared with 94% and 66%, respectively, nation-
wide [6]. Accordingly, although this region contained only 7.6%
of the total French population in 2009, it accounted for 15.6%
of all measles cases reported in France in 2011 [3].
Organizational problems, combined with social, psycholog-
ical and behavioural determinants, are the leading causes of
sub-optimal immunization levels [1]. The European Centre for
Disease Prevention and Control recently published a review of
studies conducted in Europe from January 1991 to September
2011 on knowledge, attitudes and practices of health profes-
sionals towards measles and MMR vaccination and the
influence of healthcare workers’ attitudes on parental vacci-
nation choices [7]. It retrieved 28 studies (two conducted in
France), only five of which involved GPs (including one 1998
study in France). All took place before the recent measles
outbreak in Europe. This review confirmed that healthcare
providers’ gaps in knowledge and poor communication
towards parents/patients impede high immunization rates.
Our objective was therefore to assess, by a questionnaire
survey, GPs’ knowledge, attitudes, beliefs and practices
towards measles and MMR vaccination in 2012 in southeastern
France.
Materials and Methods
Participants
This study was part of the fourth cross-sectional survey
conducted as part of the French Regional Panel of General
Practices, described elsewhere [8]. This panel survey began in
2010, aiming to study the medical practices of self-employed
GPs in southeastern France (the Provence–Alpes–Co^te d’Azur
region), which had a population of 4.89 million in 2009.
Stratified random sampling from the Ministry of Health’s
ADELI (‘Automatisation des Listes’) database, which contains
extensive information about French physicians’ practices,
selected GPs. The database was stratified for location of the
general practice (urban, suburban or rural), gender, age (<49,
49–56 or >56 years), and volume of activity, defined by the
annual number of consultations (<Q1, Q1–Q3 or >Q3).
French GPs work on a fee-for-service basis, so participants
received a compensation equivalent to two consultation fees
for their participation in each survey. Of the 1108 GPs living in
southeastern France and invited to participate in 2010, 67 (6%)
could not be contacted and 134 (12%) were ineligible
(practised only in hospitals or long-term care facilities,
practised only alternative medicine, such as homeopathy or
acupuncture, or planned to leave the region in the 6 months to
come). Of the remaining 907 GPs, 444 (49%) agreed to
participate. Those GPs who refused did not differ from
participants according to gender, age or volume of activity, but
they were less likely to practice in a rural area (p 0.035). Lack
of time was their main reason for refusal. The results
presented in this study are based on the 329 GPs who
participated in the fourth cross-sectional survey, conducted in
March–June 2012. These GPs did not differ from the 115 who
did not participate (attrition rate: 25.9% between the first and
the fourth cross-sectional surveys) according to gender, age,
location or volume of activity.
Procedure and questionnaire
Professional investigators conducted the survey by com-
puter-assisted telephone interviews. The questionnaire was
pilot-tested for clarity, length and face validity with 40 GPs.
Respondents were asked questions about their past expe-
rience with measles, their usual practices towards measles and
MMR vaccination, their knowledge of guidelines and their
beliefs about the barriers to MMR2 uptake. They were also
asked to rate their perception of the risk of complications for
five categories of patients by a five-point Likert-style response
ranging from 1, very low risk of complications, to 5, very high
risk of complications. Data were merged with data collected at
inclusion in the regional panel in June–December, 2010: GPs’
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demographic and professional characteristics and questions on
the topic of vaccinations (e.g. training and sources of informa-
tion). A random sample of one-third of the surveyed GPs was
asked two questions about MMR vaccination in children
<2 years old (the others were asked questions about hepatitis
B and influenza vaccines).
Ethics statement
The National Data Protection Authority (Commission Natio-
nale Informatique et Libertes), responsible for ethical issues
and protection of individual data in France, approved the panel
and its procedures.
Statistical analysis
Data were weighted to match the sample more closely to the
regional GP population for location of practice. All analyses
presented in this paper are weighted, but analyses without
weighting produced similar results. To compare the perceived
risk of complications between the five categories of patients
(five-point Likert-style response options, from 1 to 5), we
calculated the mean score for each category. We performed a
multivariate logistic regression to identify the factors associated
with post-exposure vaccination. Analyses were performed
using STATA/SE 12 (StataCorp., College Station, TX, USA).
Results
GP population and general vaccination practices
Table 1 summarizes the main demographic and professional
characteristics of the 329 participating GPs: 96.0% were
favourable to vaccination in general (61.8% very favourable),
and 49.5% participated in continuing medical education (CME)
courses about infectious diseases and vaccination in 2009–10.
Nearly 80% reported that they discussed the benefits and risks
of vaccination with their patients often or very often. When
they needed information concerning vaccination, 97.6%
reported consulting official or scientific sources, 78.6% Inter-
net sites, and 62.7% pharmaceutical sales representatives.
Experience with measles
These results are presented in Table 2. Perceived risk of
measles complications was highest for immunocompromised
patients (4.8), and then decreased for other categories:
pregnant women (3.9), newborn infants without co-morbidity
(3.2), 2–5-year-old children without co-morbidity (2.3) and
finally young adults without co-morbidity (2.2).
Attitudes towards MMR vaccination
Of 106 randomly selected GPs, 71 (66.8%) stated that MMR
vaccination should be mandatory for children <2 years old and
97.2% stated that they recommend MMR vaccination for that
population.
TABLE 1. Demographic and professional characteristics of
the 329 general practitioners (GPs)
Weighted (%)
Gender
Male 71.7
Female 28.3
Age (years)
<49 21.7
49–56 37.6
>56 40.7
Location of practice
Urban 82.7
Suburban 7.3
Rural 10.0
Type of practice
Solo 52.8
Group 47.2
Volume of activity (number of annual consultations)
<2849 34.3
2849–5494 50.4
>5494 15.3
Billing sector
Fixed fees 87.6
Unregulated fees 12.4
Alternative medicine
No 86.8
Occasionally 13.2
TABLE 2. General practitioners’ past experience with mea-
sles and knowledge and practices regarding measles–mumps–
rubella (MMR) vaccination (n = 326)
Weighted (%)
Past experience with measles
Treated patients with measles in 2011
Yes 44.7
Declared these cases to the health authoritiesa
Always 23.2
Often 8.1
Sometimes 10.3
Never 58.4
Ordered serology testing to confirm their clinical suspicion of measlesa
Always 19.8
Often 10.2
Sometimes 22.9
Never 47.1
Knowledge and practices regarding MMR vaccination
Reported effectiveness of two MMR doses in preventing measlesb
99% 20.3
95% 40.5
80% 33.1
50% 6.2
Checked that their patients <30 years old were up to date for their two MMR
doses
Systematically 42.4
Often 37.4
Sometimes 15.1
Never 5.1
Offered post-exposure vaccinationc
Yes 78.8
Stated the delay following contact for post-exposure vaccination as:d
24 h 40.0
72 h 44.1
1 week 8.0
Not specified 8.0
an = 147, since only general practitioners who treated measles cases in 2011 were
asked these questions.
bn = 306.
cn = 309.
dn = 239, since only general practitioners who offered post-exposure vaccination
were asked this question.
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Beliefs about barriers to MMR2 uptake
Barriers attributed to patients/parents (harmlessness of disease
and fear of adverse events) ranked first, before those reflecting
GPs’ beliefs about the vaccine and the disease (Table 3).
Knowledge and practices regarding MMR vaccination
Table 2 presents these results. Twenty percent of the GPs
knew that two MMR doses are 99% effective in preventing
measles; GPs who participated in CME courses in 2009–10
gave this correct answer more frequently (24.2% versus 15.3%,
p 0.05). The factors independently associated with offering
post-exposure vaccination were: participating in CME courses,
believing that measles is a serious disease, checking MMR
vaccination status for patients <30 years old and consulting
official or scientific sources of information (Table 4).
Discussion
Nearly half of the GPs surveyed saw patients with measles in
2011. This finding reflects the magnitude of the outbreak in
southeastern France. Lack of compliance with guidelines and
gaps in knowledge were nevertheless widespread, especially
about MMR2 and disease severity.
Vaccination with MMR is perceived rather positively in
France; a 2009 survey of 2083 French GPs showed that only 3%
were very unfavourable or rather unfavourable in their attitude
to MMR vaccination [9]. Furthermore, 94% reported routinely
or often recommending this vaccine for children aged between
1 and 2 years old [9]. In our study, 97% of GPs recommended
MMR vaccination for children <2 years old and 67% of GPs
thought that MMR vaccination should be mandatory for
children <2 years old, a higher percentage than observed in
2006 among 2027 French GPs and paediatricians: 48% and 54%,
respectively, then favoured mandatory MMR vaccination [10].
Increased awareness of measles because of the current
outbreak may have caused this marked increase.
Many surveyed GPs shared the common misconception that
measles is not a serious health threat, even though half of them
had encountered measles in 2011. Although children <5 years
old, adults, pregnant women and individuals with chronic
diseases and impaired immunity are all at high risk of measles
complications, GPs nevertheless rated the risk of complica-
tions among 2–5-year-old children and young adults without
comorbidity as low. The perception that measles is a harmless
disease was also cited by 13% of GPs as a potential barrier to
MMR2 uptake (Table 3), and it was associated with decreased
compliance with guidelines for post-exposure vaccination
(Table 4). These results illustrate what is called the vaccine
paradox, in which vaccines are essentially the victim of their
TABLE 3. Proportion of general practitioners who cited the
following items as barriers to the uptake of MMR2 (n = 326)
Weighted (%)
Barriers attributable to patients/parents
Most patients/parents consider that measles is a
harmless disease
79.8
Most patients/parents fear the vaccine’s side effectsa 50.0
Barriers attributable to general practitioners
It is often difficult to document that the patient has
received a first dose of MMR
47.6
I forget about MMR2 15.8
I consider that measles is a harmless disease 12.6
I am not convinced that MMR2 is usefula 11.5
MMR2: second dose of trivalent Measles–Mumps–Rubella vaccine.
an = 325.
TABLE 4. General practitioners’ characteristics, knowledge,
attitudes and practices associated with post-exposure vacci-
nationa (multivariate analysis, n = 280)
Variables
Adjusted
odds ratio
95% confidence
interval
General practitioners’ characteristics
Female (ref: male) 1.06 0.43–2.61
Age 49–56 (ref: <49) 0.52 0.19–1.39
Age >56 (ref: <49) 0.42 0.14–1.23
Location of practice: peri-urban (ref: urban) 1.48 0.24–9.01
Location of practice: rural (ref: urban) 1.41 0.43–4.60
Volume of activity: 2849–5494 (ref: <2849) 0.80 0.35–1.82
Volume of activity: >5494 (ref: <2849) 1.81 0.55–5.99
Group practice (ref: solo) 1.11 0.52–2.34
Billing sector: unregulated fees
(ref: fixed fees)
0.86 0.18–4.13
Occasional alternative medicine
(ref: no alternative medicine)
0.97 0.35–2.68
Attitudes towards vaccination in general
Favourable to vaccination 1.46 0.17–12.33
Discusses benefits/risks of vaccination
often/very often (ref: sometimes/never)
0.86 0.35–2.14
Participated in continuing medical
education (ref: no)
2.50* 1.24–5.02
Internet as a source of information regarding
vaccination (ref: no)
0.90 0.40–2.03
Pharmaceutical sales representatives as
a source of information (ref: no)
1.56 0.75–3.23
Official or scientific sources of information
(ref: no)
7.37* 1.15–47.11
Knowledge, attitudes and practices regarding measles and MMR
Managed patients presenting with measles in
2011 (ref: no)
1.11 0.47–2.60
Declared measles cases to Health Authorities
always/often (ref: sometimes/never)
0.73 0.26–2.03
Confirmed measles diagnostic with serology
always/often (ref: sometimes/never)
0.82 0.29–2.36
Score for the risk of complications for
young adults
1.07 0.74–1.55
Score for the risk of complications for
2–5-year-old children
1.22 0.86–1.72
Checked MMR vaccination status for
patients <30 years old always/often
(ref: sometimes/never)
3.38** 1.50–7.62
Reported an efficacy of 95 or 99% for
two MMR doses (ref: 50 or 80%)
1.11 0.55–2.25
Considered measles as a harmless disease
and perceived this as a potential barrier
to the uptake
of MMR2 (ref: no)
0.32** 0.14–0.72
Was not convinced that MMR2 is useful and
perceived this as a potential barrier to the
uptake of MMR2 (ref: no)
0.77 0.24–2.42
MMR2: second dose of trivalent measles–mumps–rubella vaccine.
aPost-exposition vaccination consists of offering MMR vaccination to non-immune
relatives in contact with a patient presenting measles.
*p <0.05; **p <0.01.
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own success [1]. After an effective and safe vaccine is
introduced, vaccination coverage increases and disease inci-
dence decreases dramatically. The perceived risk of the disease
and its complications then fall as well. The disease is no longer
remembered as dangerous, and adverse events—real or
alleged—following immunization become the main concern.
Even healthcare providers pay less attention to the disease and
its consequences, and effective communication with parents or
patients suffers [1].
Lack of compliance with guidelines was common. GPs
reported fewer than half the cases they saw, as others have
also noted [4,11]. They ordered serology to confirm clinically
suspected disease infrequently. Only 42% systematically com-
plied with the catch-up vaccination programme for all people
born in 1980 or later. They did not provide post-exposure
vaccination in 21% of cases. However, CME positively affected
GPs’ level of knowledge about the effectiveness of two MMR
doses and their level of compliance with guidelines for
post-exposure vaccination. Consulting official or scientific
sources of information about vaccination was also associated
with improved compliance with post-exposure vaccination.
Coverage rates for MMR2 are clearly insufficient in France:
66% in 2003–04 for children aged 15 years [6]. Of the measles
cases reported in France from 2008 to 30 April 2011, 86% of
the children had not been vaccinated, 11% had received one
MMR dose and 3% had received two MMR doses [12]. Our
study shows that GPs’ strongly underestimate the effectiveness
of two doses of MMR: only 20% of them selected the correct
effectiveness rate—99%. A British survey showed that 40% of
the 136 responding GPs were unsure of the need for the
second dose and around 10% thought it unnecessary [13].
Another survey in the UK found that only 46% of GPs
reported feeling very confident about explaining the rationale
of a two-dose schedule to a well-informed parent [14]. In our
study, we explored the potential barriers to MMR2 uptake and
identified several factors amenable to change. Most GPs
declared that parents/patients consider measles a harmless
disease (80%); half reported that parents/patients fear the
vaccine’s side effects (50%). These perceptions substantially
overestimate the barriers reported by French parents [15].
This discrepancy might reflect gaps in communication, as
shownbyothers forMMR [16]. The EuropeanCentre forDisease
Prevention and Control review showed that parents in Europe
regard doctors and other healthcare providers as the most
reliable source of information, but the provision of inadequate or
vague information can compromise parents’ trust of healthcare
workers, of the latter’s knowledge about the vaccine’s safety and
efficacy, and even of their motives to vaccinate [7].
The GPs in our survey also frequently reported organiza-
tional issues, including difficulties in accessing the vaccination
record (48%) and a lack of systematic reminders for MMR2
(16%). Electronic vaccine records could be very helpful,
combined with postal reminders. Finally, our survey showed
that a non-negligible proportion of GPs had misconceptions
about the potential severity of measles (13%) and the
usefulness of MMR2 (12%); mandatory CME courses could
be a way to increase knowledge.
Our study brings original information but has some
limitations. First, the initial participation rate in the French
Regional Panel of General Practices was 49.0% in southeastern
France and the attrition rate between the first and the fourth
cross-sectional surveys was 25.9%. This participation rate is
nonetheless relatively high for physician panels requiring
repeated participation (see for example [17]: response
rate = 19%). We cannot rule out the possibility that GPs
who agreed to participate in the panel differed from non-par-
ticipants concerning their views on measles and MMR vacci-
nation, although the measles topic was not mentioned before
GPs were asked to participate. Second, it would have been
interesting to investigate the vaccination coverage/vaccine
acceptance rates in the population served by each doctor, to
assess the effectiveness of their active offers of MMR;
unfortunately, these data were unavailable.
In conclusion, a multi-component approach is essential to
reach the vaccination coverage required to eliminate measles
in France [1]. Improving vaccination coverage requires increas-
ing GPs’ awareness of this disease and filling in any gaps in their
knowledge, by providing them with evidence-based informa-
tion on measles/MMR and educating them to communicate
effectively with patients and parents. Specific official websites
and the inclusion of vaccine education in a mandatory CME
curriculum are potential means of reaching these goals [7]. In
addition, both GPs and the public must be convinced that
measles is not a harmless disease. Finally, the development of
electronic vaccine records would facilitate vaccination for both
physicians and parents/patients.
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